As of 2025-07-01, the Intrinsic Value of Corcept Therapeutics Inc (CORT) is 56.59 USD. This CORT valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 73.40 USD, the upside of Corcept Therapeutics Inc is -22.90%.
The range of the Intrinsic Value is 36.05 - 149.68 USD
Based on its market price of 73.40 USD and our intrinsic valuation, Corcept Therapeutics Inc (CORT) is overvalued by 22.90%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 36.05 - 149.68 | 56.59 | -22.9% |
| DCF (Growth 10y) | 44.85 - 175.37 | 68.53 | -6.6% |
| DCF (EBITDA 5y) | 18.62 - 29.69 | 22.61 | -69.2% |
| DCF (EBITDA 10y) | 26.00 - 39.51 | 30.91 | -57.9% |
| Fair Value | 11.75 - 11.75 | 11.75 | -83.99% |
| P/E | 17.08 - 28.93 | 21.60 | -70.6% |
| EV/EBITDA | 9.70 - 21.61 | 14.96 | -79.6% |
| EPV | 14.80 - 17.54 | 16.17 | -78.0% |
| DDM - Stable | 13.05 - 47.02 | 30.03 | -59.1% |
| DDM - Multi | 19.80 - 56.09 | 29.35 | -60.0% |
| Market Cap (mil) | 7,783.34 |
| Beta | 0.18 |
| Outstanding shares (mil) | 106.04 |
| Enterprise Value (mil) | 7,693.52 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.60% |
| Cost of Debt | 5.00% |
| WACC | 6.47% |